Evidence map›Paper›PMID 31501784›Full record

ReviewClinical and experimental hepatology2019

Epidemiology of gallbladder cancer.

Prashanth Rawla, Tagore Sunkara, Krishna Chaitanya Thandra, Adam Barsouk

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical and experimental hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04211168 (Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers), which is not on this map. Cited by 174 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
174citing papers in PubMed, 5 pooled it
28.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04211168 phase2unknown statusnot on this mapstarted 2020, after this paper: background citation

Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study

TypeinterventionalSponsorPeking Union Medical College HospitalRan2020 to 2024Enrolled44ConditionsAdvanced Biliary Tract CancerArmsToripalimab plus Lenvatinib
3 · Its place in the literature

Who cites it

174 citing papers in PubMed, 5 syntheses or guidelines pooled it, 344 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. The Chile BiLS case-control study of gallbladder cancer.Archives of public health = Archives belges de sante publique · 2026
    Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article

114 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

Prashanth RawlaDepartment of Internal Medicine/Hospitalist, Sovah Health, Martinsville, VA, United States.
Tagore SunkaraDivision of Gastroenterology and Hepatology, Mercy Medical Center, Des Moines, IA, United States.
Krishna Chaitanya ThandraDepartment of Pulmonary and Critical Care Medicine, Sentara Virginia Beach General Hospital, Virginia Beach, VA, United States.
Adam BarsoukHillman Cancer Center, University of Pittsburgh, PA, United States.
Mercy Medical Center · USSentara Virginia Beach General Hospital · USSovah Health Martinsville · USUPMC Hillman Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

According to GLOBOCAN 2018 data, gallbladder cancer (GBC) accounts for 1.2% of all global cancer diagnoses, but 1.7% of all cancer deaths. Only 1 in 5 GBC cases in the United States is diagnosed at an early stage, and median survival for advanced stage cancer is no more than about a year. The incidence of the disease is increasing in the developed world. Gallstones, biliary cysts, carcinogen exposure, typhoid, and Helicobacter pylori infection, and abnormal pancreaticobiliary duct junctions are all risk factors, many of which account for its geographical, ethnic and sex distribution. Genetics also plays a strong role, as about a quarter of GBC cases are considered familial, and certain ethnicities, such as Native Americans, are at far higher risk for the neoplasm. Prevention includes weight loss, vaccination against and treatment of bacterial infections, early detection and elimination of polyps and cysts, and avoidance of oral estrogen replacement therapy.

Indexed as

etiologyincidencemortalityrisk factorsurvival

Identifiers

PMID31501784
PMCPMC6728871
OpenAlexW2947521241

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.